Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Nelson Syndrome × pasireotide × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 3 Neuroendocrine Tumors 3 Prostatic Neoplasms 2 Neoplasm Metastasis 2 Multiple Myeloma 2 Carcinoid Tumor 2 Uveal Melanoma 1 Thyroid Neoplasms 1 Sarcoma, Synovial 1 Prolactinoma 1 Prolactin-Producing Pituitary Tumor 1 Primary Inoperable Thymoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Peritoneal Neoplasms 1 Pancreatic Fistula 1 Neoplasms 1 Nelson Syndrome 1 Myelodysplastic Syndromes 1 Meningioma 1 Lymphoma 1 Liver Neoplasms 1 Leukemia, Myeloid, Acute 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Insulinoma 1 Hypoglycemia 1 Hyperinsulinism 1 Hematologic Neoplasms 1 Gastro-enteropancreatic neuroendocrine tumor 1 Desmoplastic Small Round Cell Tumor 1 Congenital Hyperinsulinism 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01617733 2016-11-02

Pasireotide Therapy in Patients With Nelson's Syndrome

Sheffield Teaching Hospitals NHS Foundation Trust

Phase 2 Terminated

Nelson Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡